Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies. The regions covered by these partnerships include the European Union, Middle East and North Africa (MENA), South Africa, Israel, Canada, Brazil and Columbia.
Lotus will be responsible for the development and manufacturing of the products for its partners that include Lenalidomide, Sunitinib, Enzalutamide.
This is another step forward for the Alvo family, driven by the inception of Adalvo and a continued focus on B2B growth. Along with this announcement, recent partnership agreements have also been made for products still under development coming from Lotus’ leading oncology portfolio.
"We are excited to partner with Lotus to deliver these new commercial partnerships in various regions. By expanding our global footprint, we are able to impact more patients around the world and give better access to the products we deliver. This is just the beginning in terms of the commercial partnerships Adalvo are working on with Lotus. I look forward to growing together and lending Adalvo’s support to continue building relationships."
"We are pleased to have been able to strike agreements with these leading pharmaceutical companies. In doing so, we are diversifying our revenue base outside the APAC region and positioning Lotus as a global leader in oncology medicines and complex generics. The partnerships will also benefit patients around the world, which now may have better access to high quality medicines. The series of agreements are the product of a hard-working B2B team which is driven by the pursuit of delivering profitable growth, which can be reinvested in R&D, high-quality manufacturing, services and partnerships."